GlassScriptPhysician profile
Alan Nicholas Snyder
NPI 1184299893
$13,082.87
in general payments reported to CMS, 2019-2025
26 companies · $2,432 in 2025
The $2,432 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $225 · 2022: $661 · 2023: $7,395 · 2024: $2,369 · 2025: $2,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,267 · Consulting Fee: $4,661 · Travel and Lodging: $838 · Education: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,267.41 |
| Consulting Fee | $4,660.53 |
| Travel and Lodging | $838.05 |
| Education | $430.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $6,906.65 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $681.77 | 2022-2025 | Tremfya |
| Ucb, INC. | $581.23 | 2022-2024 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $545.26 | 2023-2025 | Oracea, Epsolay, Nemluvio |
| Abbvie INC. | $474.25 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $429.16 | 2023-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $364.91 | 2025 | |
| Janssen Biotech, INC. | $340.17 | 2023-2025 | Tremfya, Stelara |
| Leo Pharma INC. | $324.04 | 2023-2024 | Adbry |
| Arcutis Biotherapeutics, INC. | $273.67 | 2023-2025 | Zoryve |
| Blueprint Medicines Corporation | $262.33 | 2025 | |
| Biofrontera INC. | $249.06 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.61 | 2023-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $227.05 | 2024-2025 | Cabtreo, Jublia, Siliq |
| Lilly USA, LLC | $205.39 | 2023-2025 | Taltz, Olumiant, Ebglyss |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $154.27 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $135.62 | 2023-2024 | Sotyktu |
| Amgen INC. | $134.00 | 2025 | Otezla, Amjevita |
| Krystal Biotech INC | $119.70 | 2023 | Vyjuvek |
| Regeneron Pharmaceuticals, INC. | $118.31 | 2024 | Dupixent |
| Almirall LLC | $103.25 | 2023-2025 | Klisyri |
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 | |
| Dermavant Sciences, INC. | $38.19 | 2024 | Vtama |
| Pierre Fabre Pharmaceuticals, INC. | $34.51 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $27.62 | 2024 | Libtayo |
| Verrica Pharmaceuticals INC. | $21.86 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.